Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Stevanato Group has presented a mixed performance in the second quarter of 2024, which led to revised expectations for its annual outlook.</li><li>On the positive side, the company reported a 2% increase in revenue to EUR 260 million, driven by a strong performance in the Biopharmaceutical and Diagnostic Solutions (BDS) segment, which saw a 9% growth.</li><li>This growth was largely fueled by high-performance syringes, contributing significantly to the product diversity and revenue from high-value solutions, which increased by 23%.</li></ul>

Stevanato Group has presented a mixed performance in the second quarter of 2024, which led to revised expectations for its annual outlook.On the positive side, the company reported a 2% increase in revenue to EUR 260 million, driven by a strong performance in the Biopharmaceutical and Diagnostic Solutions (BDS) segment, which saw a 9% growth.This growth was largely fueled by high-performance syringes, contributing significantly to the product diversity and revenue from high-value solutions, which increased by 23%.

Stevanato Group S.p.A.: Expansion & Efficiency In Product Lines & Other Major Drivers

<ul><li>Stevanato Group's second quarter 2024 earnings results reflect a mixed performance characterized by robust revenue growth in the Biopharmaceutical and Diagnostic Solutions (BDS) segment, offset by challenges in the Engineering segment.</li><li>Challenges included project delays and higher costs primarily related to supply chain disruptions.</li><li>Stevanato Group provided comprehensive updates on operational initiatives aimed at optimizing production and improving efficiency across their locations, especially in Denmark and Italy.</li></ul>

Stevanato Group's second quarter 2024 earnings results reflect a mixed performance characterized by robust revenue growth in the Biopharmaceutical and Diagnostic Solutions (BDS) segment, offset by challenges in the Engineering segment.Challenges included project delays and higher costs primarily related to supply chain disruptions.Stevanato Group provided comprehensive updates on operational initiatives aimed at optimizing production and improving efficiency across their locations, especially in Denmark and Italy.

Stevanato Group S.p.A.: What Is Their Market Outlook & How Are They Adapting To Customer and Regulatory Requirements? - Major Drivers

<ul><li>Stevanato Group's first quarter 202rb performance underlined some critical challenges while also highlighting its robust positioning within the pharmaceutical supply sector.</li><li>In a period marred by the ripples of the pandemic induced stockpiling, Stevanato Group's revenue saw a slight decrement of 1% year-over-year, totaling EUR 236 million.</li><li>This decline predominantly stemmed from the accelerated industry-wide destocking processes, particularly impacting their EZ-fill vials segment.</li></ul>

Stevanato Group's first quarter 202rb performance underlined some critical challenges while also highlighting its robust positioning within the pharmaceutical supply sector.In a period marred by the ripples of the pandemic induced stockpiling, Stevanato Group's revenue saw a slight decrement of 1% year-over-year, totaling EUR 236 million.This decline predominantly stemmed from the accelerated industry-wide destocking processes, particularly impacting their EZ-fill vials segment.

Stevanato Group S.p.A.: Leveraging Market Trends in Biologics and Self-Administration! - Major Drivers

<ul><li>Stevanato Group reported a positive 2023 stating a growth of 10% or 11% in constant currency terms.</li><li>As per Executive Chairman of the company, Franco Stevanato, the group has seen continued growth despite the inflation uncertainty and ongoing supply chain issues.</li><li>According to the chairman, while these dynamics have been challenging to navigate, they have simultaneously facilitated the growth of high-value solutions within Stevanato Group's business model.</li></ul>

Stevanato Group reported a positive 2023 stating a growth of 10% or 11% in constant currency terms.As per Executive Chairman of the company, Franco Stevanato, the group has seen continued growth despite the inflation uncertainty and ongoing supply chain issues.According to the chairman, while these dynamics have been challenging to navigate, they have simultaneously facilitated the growth of high-value solutions within Stevanato Group's business model.

Stevanato Group S.p.A.: Initiation Of Coverage - The Rising Demand for Biologics Catalyzing Growth? - Major Drivers

Italy

Stevanato Group Societa' Per Azioni manufactures packaging containers from glass. The Company provides vials, ampoules, auto-injectors, and prefilled syringes for pharmaceutical industry. Stevanato Group serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Stevanato Group SpA (STVN US)

Stevanato Group S.p.A.: Expansion & Efficiency In Product Lines & Other Major Drivers

Stevanato Group has presented a mixed performance in the second quarter of 2024, which led to revised expectations for its annual outlook. On the...

Baptista Research

Stevanato Group S.p.A.: What Is Their Market Outlook & How Are They Adapting To Customer and Regulatory Requirements? - Major Drivers

Stevanato Group's second quarter 2024 earnings results reflect a mixed performance characterized by robust revenue growth in the Biopharmaceutical...

Baptista Research

Stevanato Group S.p.A.: Leveraging Market Trends in Biologics and Self-Administration! - Major Drivers

Stevanato Group's first quarter 202rb performance underlined some critical challenges while also highlighting its robust positioning within the...

Baptista Research

Stevanato Group S.p.A.: Initiation Of Coverage - The Rising Demand for Biologics Catalyzing Growth? - Major Drivers

Stevanato Group reported a positive 2023 stating a growth of 10% or 11% in constant currency terms. As per Executive Chairman of the company,...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)